已关闭
  • 顶部Banner位
  • 固定模块
设置
BPD
试用
AI
企业管理端
厂家
PTEN (phospho Ser385) Rabbit Polyclonal Antibody
收藏 收藏
分享
原料试剂 研发实验室
价格
¥1350.00
品牌 EnkiLife/恩玑
地区 中国,湖北省,武汉市
货号 APRab05314
产地 国产
选择规格
50μL
易享客服
EnkiLife
武汉EnkiLife-log科技有限公司
武汉
营业执照已审核
武汉恩玑生命科技有限公司(EnkiLife)是一家聚焦细胞生物学和免疫学的生物技术企业,致力于为生命科学行业的科研工作者提供高质量的产品和卓越的客户服务。 EnkiLife的产品线包括细胞系、原代细胞、培养基、血清、细胞检测试剂盒、蛋白、抗体、ELISA试剂盒、生化试剂盒等,并提供技术服务与定制开发,全方位满足生命科学行业需求,为您的实验保驾护航! EnkiLife的技术团队凭借在生物科学领域的丰富经验和专业知识,已在公司内部构建了一套完善的技术平台,涵盖细胞培养及检测、蛋白表达、抗体制备以及免疫学等多个关键领域。我们始终秉承严格的质量管理体系,优化生产流程,确保为客户提供高效、精准的技术支持。 展望未来,EnkiLife将继续致力于技术创新,不断丰富和完善我们的技术平台,以更好地满足客户需求,同时不断提升服务水平,确保客户体验的持续优化。我们期待与更多的全球科研工作者携手合作,共同推动生命科学领域的进步与发展。
进入店铺
产品规格 图文详情 技术文档
产品规格
品牌名称
EnkiLife/恩玑
货号
APRab05314
国产/进口
国产
规格
50μL
图文详情

产品概述

产品名称(Product Name)

PTEN (phospho Ser385) Rabbit Polyclonal Antibody

描述(Description)

Rabbit Polyclonal Antibody

宿主(Host)

Rabbit

应用(Application)

IHC,ELISA

种属反应性(Reactivity)

Human,Mouse,Rat

 

产品性能

偶联物(Conjugation)

Unconjugated

修饰(Modification)

Phospho Antibody

同种型(Isotype)

IgG

克隆(Clonality)

Polyclonal

形式(Form)

Liquid

存放说明(Storage)

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

储存溶液(Buffer)

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N.

纯化方式(Purification)

Affinity purification

 

免疫原

免疫原信息(Immunogen Information)

0

基因名(Gene Name)

PTEN

别名(Alternative Names)

PTEN; MMAC1; TEP1; Phosphatidylinositol 3; 4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; Mutated in multiple advanced cancers 1; Phosphatase and tensin homolog

基因ID(Gene ID)

5728

蛋白ID(SwissProt ID)

P60484

 

产品应用

稀释比(Dilution Ratio)

IHC 1:100-1:300 ELISA: 1:5000

蛋白分子量(Molecular Weight)

 

研究背景

This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded by this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. The use of a non-canonical (CUG) upstream initiation site produces a longer isoform that initiates translation with a leucine, and is thought to be preferentially associated with the mitochondrial inner membrane. This longer isoform may help regulate enercatalytic activity:A phosphoprotein + H(2)O = a protein + phosphate.,catalytic activity:Phosphatidylinositol 3,4,5-trisphosphate + H(2)O = phosphatidylinositol 4,5-bisphosphate + phosphate.,catalytic activity:Protein tyrosine phosphate + H(2)O = protein tyrosine + phosphate.,cofactor:Magnesium.,disease:A microdeletion of chromosome 10q23 involving PTEN and BMPR1A is a cause of chromosome 10q23 deletion syndrome [MIM:612242]. This syndrome shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.,disease:Defects in PTEN are a cause of Bannayan-Zonana syndrome (BZS) [MIM:153480]; also known as Ruvalcaba-Riley-Smith or Bannayan-Riley-Ruvalcaba syndrome (BRRS). In BZS there seems not to be an increased risk of malignancy. It has a partial clinical overlap with CD. BZS is characterized by the classic triad of macrocephaly, lipomatosis and pigmented macules of the gland penis.,disease:Defects in PTEN are a cause of Cowden disease (CD) [MIM:158350]; also known as Cowden syndrome (CS). CD is an autosomal dominant cancer predisposition syndrome associated with elevated risk for tumors of the breast, thyroid and skin. The predominant phenotype for CD is multiple hamartoma syndrome, in many organ systems including the breast (70% of CD patients), thyroid (40-60%), skin, CNS (40%), gastrointestinal tract. Affected individuals are at an increased risk of both breast and thyroid cancers. Trichilemmomas (benign tumors of the hair follicle infundibulum), and mucocutaneous papillomatosis (99%) are hallmarks of CD.,disease:Defects in PTEN are a cause of macrocephaly/autism syndrome [MIM:605309]. Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD).,disease:Defects in PTEN are a cause of oligodendroglioma [MIM:137800]; also called oligodendroblastoma or familial glioma of brain. Oligodendroglioma is a usually benign neoplasm derived from and composed of oligodendrogliocytes in varying stages of differentiation. The majority are seen in adults in the white matter of the brain.,disease:Defects in PTEN are a cause of Proteus syndrome [MIM:176920]. Proteus syndrome is a hamartomatous disorder characterized by overgrowth of multiple tissues, connective tissue and epidermal naevi, and vascular malformations. These presentations are usually apparent at birth or soon after and continue to develop as the patient ages. It is named after the Greek god Proteus who, legend has it, could change his shape at will to avoid capture. Tumors, mostly benign but some malignant, have also been reported in Proteus syndrome, generally presenting by the age of 20 years and including papillary adenocarcinoma of the testis, meningioma, and cystadenoma of the ovaries.,disease:Defects in PTEN are a cause of squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355].,disease:Defects in PTEN are a cause of susceptibility to endometrial cancer [MIM:608089].,disease:Defects in PTEN are a cause of VACTERL association with hydrocephalus [MIM:276950]; which includes also VATER association with hydrocephalus. VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects.,disease:Defects in PTEN are involved in prostate cancer [MIM:176807].,disease:Defects in PTEN are the cause of Lhermitte-Duclos disease (LDD) [MIM:158350]; also known as cerebelloparenchymal disorder VI. LDD is characterized by dysplastic gangliocytoma of the cerebellum which often results in cerebellar signs and seizures. LDD and CD seem to be the same entity, and are considered as hamartoma-neoplasia syndromes.,disease:Mutations of PTEN are found in a large number of cancers.,domain:The C2 domain binds phospholipid membranes in vitro in a Ca(2+)-independent manner; this binding is important for its tumor suppressor function.,function:Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue.,induction:Down-regulated by transforming growth factor beta (TGF-beta).,PTM:Phosphorylated in vitro by MAST1, MAST2 and MAST3. Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit or promote PDZ-binding.,similarity:Contains 1 C2 tensin-type domain.,similarity:Contains 1 phosphatase tensin-type domain.,subunit:Monomer. The unphosphorylated form interacts with the second PDZ domain of AIP1 and with DLG1 and MAST2 in vitro. Interacts with MAGI2, MAGI3, MAST1 and MAST3, but neither with MAST4 nor with DLG5. Interaction with MAGI2 increases protein stability.,tissue specificity:Expressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas.,

 

研究领域

Insulin Receptor; Regulation_Microtubule; B Cell Receptor; mTOR; Akt_PKB; Protein_Acetylation

技术文档
没有您想要的资料?去索要
返回顶部